FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741171761> ?p ?o ?g. }

• W2741171761 abstract "In patients with acute myeloid leukemia (AML) (≥ 60 years) and myelodysplastic syndrome (MDS), the use of hypomethylating agents (HMAs) may extend survival, but cure rates are very low and new treatment approaches are needed. HMAs, such as azacitidine, work by inhibiting DNMT1, leading to depletion of DNA methylation in the tumor cells. Hypomethylation, in turn, leads to the re-expression of genes associated with differentiation and growth arrest. We have recently explored the potent and selective RARα agonist SY-1425 in a genomically defined subset of AML. SY-1425 binds to RARα and causes a transition from repression to strong activation of target genes, thus reprogramming the tumor cells toward terminal maturation in RARA-high AML models, supporting our recently initiated Phase 2 trial in a biomarker-selected subset of AML and MDS (NCT02807558). Based on potential mechanistic synergy, we evaluated SY-1425 in combination with HMAs and identified a synergistic anti-proliferative effect. In RARA-high AML cell lines, but not RARA-low, the combination of SY-1425 with either azacitidine or decitabine showed synergistic anti-proliferative effects on the cells, with combination indices less than 0.5 over a range of concentrations from 0.01 to 100nM of SY-1425 and 0.1 to 1µM of HMAs. SY-1425 and azacitidine were also co-administered to a disseminated patient-derived xenograft (PDX) mouse model of RARA-high AML. The combination demonstrated superior reduction of tumor burden vs either therapy alone, leading to deeper and more durable responses with less than 1% detectable tumor burden. A follow-up study in the RARA-high PDX model investigated different treatment schedules of SY-1425 and azacitidine over a period of 56 days, supporting a regimen that maximizes anti-tumor activity and tolerability. Mechanistic studies using RNA-seq and ChIP-seq in AML cell line models have revealed that while azacitidine had only moderate suppressive or activating effects over a broad set of genes, the addition of SY-1425 in RARA-high models resulted in strong and specific induction of genes bound by RARα. It is hypothesized that azacitidine acts to prime the tumor cells for reprogramming by SY-1425. The loss of methyl-cytosine residues following azacitidine treatment lowers the barrier to SY-1425 mediated gene induction. It was observed that the two agents work cooperatively to promote terminal differentiation and decrease proliferation of the AML tumor cells, with the potential for increased clinical benefit in a subset of AML defined by a RARA super-enhancer. Based on the largely non-overlapping clinical toxicity profiles of azacitidine and SY-1425, supported by the observed tolerability of the combination in preclinical models, these findings provide a strong rationale for a planned study of this combination in biomarker selected, newly diagnosed AML patients. Citation Format: Michael R. McKeown, Emily Lee, Chris Fiore, Matthew L. Eaton, Christian C. Fritz, Eric Olson. SY-1425 (tamibarotene), a selective RARα agonist, shows synergistic anti-tumor activity with hypomethylating agents in a biomarker selected subset of AML [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3085. doi:10.1158/1538-7445.AM2017-3085" @default.
• W2741171761 created "2017-08-08" @default.
• W2741171761 creator A5005983640 @default.
• W2741171761 creator A5022575622 @default.
• W2741171761 creator A5023553117 @default.
• W2741171761 creator A5032421989 @default.
• W2741171761 creator A5042782105 @default.
• W2741171761 creator A5074794038 @default.
• W2741171761 date "2017-07-01" @default.
• W2741171761 modified "2023-09-27" @default.
• W2741171761 title "Abstract 3085: SY-1425 (tamibarotene), a selective RARα agonist, shows synergistic anti-tumor activity with hypomethylating agents in a biomarker selected subset of AML" @default.
• W2741171761 doi "https://doi.org/10.1158/1538-7445.am2017-3085" @default.
• W2741171761 hasPublicationYear "2017" @default.
• W2741171761 type Work @default.
• W2741171761 sameAs 2741171761 @default.
• W2741171761 citedByCount "0" @default.
• W2741171761 crossrefType "proceedings-article" @default.
• W2741171761 hasAuthorship W2741171761A5005983640 @default.
• W2741171761 hasAuthorship W2741171761A5022575622 @default.
• W2741171761 hasAuthorship W2741171761A5023553117 @default.
• W2741171761 hasAuthorship W2741171761A5032421989 @default.
• W2741171761 hasAuthorship W2741171761A5042782105 @default.
• W2741171761 hasAuthorship W2741171761A5074794038 @default.
• W2741171761 hasConcept C104317684 @default.
• W2741171761 hasConcept C121608353 @default.
• W2741171761 hasConcept C126322002 @default.
• W2741171761 hasConcept C150194340 @default.
• W2741171761 hasConcept C190727270 @default.
• W2741171761 hasConcept C2776012956 @default.
• W2741171761 hasConcept C2776239401 @default.
• W2741171761 hasConcept C2778729363 @default.
• W2741171761 hasConcept C2780007613 @default.
• W2741171761 hasConcept C2780235182 @default.
• W2741171761 hasConcept C2780817109 @default.
• W2741171761 hasConcept C33288867 @default.
• W2741171761 hasConcept C502942594 @default.
• W2741171761 hasConcept C54355233 @default.
• W2741171761 hasConcept C71924100 @default.
• W2741171761 hasConcept C86803240 @default.
• W2741171761 hasConcept C98274493 @default.
• W2741171761 hasConceptScore W2741171761C104317684 @default.
• W2741171761 hasConceptScore W2741171761C121608353 @default.
• W2741171761 hasConceptScore W2741171761C126322002 @default.
• W2741171761 hasConceptScore W2741171761C150194340 @default.
• W2741171761 hasConceptScore W2741171761C190727270 @default.
• W2741171761 hasConceptScore W2741171761C2776012956 @default.
• W2741171761 hasConceptScore W2741171761C2776239401 @default.
• W2741171761 hasConceptScore W2741171761C2778729363 @default.
• W2741171761 hasConceptScore W2741171761C2780007613 @default.
• W2741171761 hasConceptScore W2741171761C2780235182 @default.
• W2741171761 hasConceptScore W2741171761C2780817109 @default.
• W2741171761 hasConceptScore W2741171761C33288867 @default.
• W2741171761 hasConceptScore W2741171761C502942594 @default.
• W2741171761 hasConceptScore W2741171761C54355233 @default.
• W2741171761 hasConceptScore W2741171761C71924100 @default.
• W2741171761 hasConceptScore W2741171761C86803240 @default.
• W2741171761 hasConceptScore W2741171761C98274493 @default.
• W2741171761 hasLocation W27411717611 @default.
• W2741171761 hasOpenAccess W2741171761 @default.
• W2741171761 hasPrimaryLocation W27411717611 @default.
• W2741171761 hasRelatedWork W1970263496 @default.
• W2741171761 hasRelatedWork W2019142623 @default.
• W2741171761 hasRelatedWork W2056594138 @default.
• W2741171761 hasRelatedWork W2088399561 @default.
• W2741171761 hasRelatedWork W2293890571 @default.
• W2741171761 hasRelatedWork W2312499162 @default.
• W2741171761 hasRelatedWork W2322553378 @default.
• W2741171761 hasRelatedWork W2560296882 @default.
• W2741171761 hasRelatedWork W2561336479 @default.
• W2741171761 hasRelatedWork W2575464554 @default.
• W2741171761 hasRelatedWork W2673359900 @default.
• W2741171761 hasRelatedWork W2795339996 @default.
• W2741171761 hasRelatedWork W2885485321 @default.
• W2741171761 hasRelatedWork W2887266942 @default.
• W2741171761 hasRelatedWork W2916665060 @default.
• W2741171761 hasRelatedWork W2953415312 @default.
• W2741171761 hasRelatedWork W2954624728 @default.
• W2741171761 hasRelatedWork W3006513842 @default.
• W2741171761 hasRelatedWork W3014584171 @default.
• W2741171761 hasRelatedWork W3080386471 @default.
• W2741171761 isParatext "false" @default.
• W2741171761 isRetracted "false" @default.
• W2741171761 magId "2741171761" @default.
• W2741171761 workType "article" @default.